Advertisement

Drugs & Therapy Perspectives

, Volume 11, Issue 2, pp 1–5 | Cite as

Cefpirome: another broadsword in the war against severe hospital-acquired infections?

New Drugs and Disease Management
  • 7 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Wiseman LR, Lamb, HM. Cefpirome: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy in the treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997 Jul; 54(1): 117–40PubMedCrossRefGoogle Scholar
  2. 2.
    British National Formulary No. 32. London: The Pharmaceutical Press, 1997 Sep: 241–7Google Scholar
  3. 3.
    1997 Physicians GenRx. St Louis, Missouri: Mosby-Year Book, Inc., 1997: pp. II-373–77; II-462–68Google Scholar
  4. 4.
    Drugs & Therapy Perspectives. Cefepime: a new cephalosporin for parenteral treatment of serious infections. 1994; 4(3): 8 Aug: 4–7Google Scholar
  5. 5.
    Rains CP, Bryson HM, Peters DH. Ceftazidime: an update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 49: 577–617, 1995PubMedCrossRefGoogle Scholar
  6. 6.
    Balfour JA, Bryson HM, Brogden RN. Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Drugs 51: 99–136, 1996PubMedCrossRefGoogle Scholar
  7. 7.
    Wolff M, Carbon C, Falissard B, et al. Comparative study of cefpirome (CPO) and ceftazidime (CAZ) in ICU patients with pneumonia [abstract no. LM21]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15–18; New Orleans, USA: 1996; 284Google Scholar
  8. 8.
    Legall JR, Leleu G, Orvain J, et al. Efficacy of cefpirome in patients with severe pneumonia [abstract]. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1993 Oct 17–20: New Orleans, USA; 1993; 290Google Scholar
  9. 9.
    Norrby SR, Geddes AM, Shah PM, et al. Cefpirome (CPO) vs ceftazidime (CAZ) as empirical sepsis treatment [abstract no. CE0329]. 20th International Congress of Chemotherapy; 1997 Jun 29-Jul 3; Sydney, AustraliaGoogle Scholar
  10. 10.
    Open, controlled, randomised, multiclinic, comparative study of the efficacy, safety and tolerance of cefpirome (HR810) versus ceftazidime in the empiric treatment of patients with suspected bacteraemia/sepsis. Hoechst Marion Roussel, data on file. HR810/2/MN/302/SP; Feb 14 1997Google Scholar
  11. 11.
    Norrby SR, Geddes AM. Efficacy of cefpirome in the treatment of septicaemia. Scand J Infect Dis 1993; Suppl. 91: 51–9Google Scholar
  12. 12.
    Carbon C, Gonzalez OR, Dictar M, et al. Prospective randomized phase II study of intravenous cefpirome 1g or 2g bd in the treatment of hospitalized patients with different infections. J Antimicrob Chemother 1992 Apr; 29 Suppl. A: 87–94PubMedGoogle Scholar
  13. 13.
    Reiffers J, Cony MP, Pris J, et al. Efficacy of cefpirome in the initial empirical management of febrile neutropenic patients with hematological malignancies [abstract]. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1992 Oct 11–14; Anaheim, USA: 1992; 373Google Scholar
  14. 14.
    Browett P, Schwarer A, Whitby M, et al. Comparison of cefpirome/gentamicin and piperacillin/gentamicin as empirical therapy for neutropenic fever [abstract]; 1997; data on fileGoogle Scholar
  15. 15.
    Rubinstein E, Labs R, Reeves A. A review of the adverse events profile of cefpirome. Drug Saf 1993 Nov; 9: 340–5PubMedCrossRefGoogle Scholar
  16. 16.
    Cefpirome. Prescrire International 1995 Aug; 4 (18): 110Google Scholar
  17. 17.
    Vincent J-L, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European prevalence of infection in intensive care study. JAMA 1995; 274: 639–44PubMedCrossRefGoogle Scholar
  18. 18.
    Committee of the Scientific Assembly on Microbiology. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and prevention strategies. A consensus statement. Am J Respir Crit Care Med 1995; 153: 1711–25Google Scholar
  19. 19.
    Glauser M, Boogaerts M, Cordonnier C, et al. Empiric therapy of bacterial infections in severe neutropenia. Clin Microbiol Infect 1997 Apr; 3 Suppl. 1: S77–86CrossRefGoogle Scholar
  20. 20.
    Bodey GP, Nies BA, Mohberg NR, et al. Imipenem/cilastatin therapy of infections in cancer patients. Cancer 1987; 60: 255–62PubMedCrossRefGoogle Scholar
  21. 21.
    Sanders JW, Powe NR, Moore RD. Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a metaanalysis. J Infect Dis 1991 Nov; 164: 907–16PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1998

Personalised recommendations